Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Olutasidenib |
Trade Name | Rezlidhia |
Synonyms | FT-2102 |
Drug Descriptions |
Rezlidhia (olutasidenib) targets IDH1 R132 mutations, leading to decreased 2HG production and potentially promoting differentiation and decreasing proliferation of IDH R132-mutant cancer cells (PMID: 31971798). Rezlidhia (olutasidenib) is FDA approved for use in adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation (FDA.gov). |
DrugClasses | IDH1 Inhibitor 8 |
CAS Registry Number | 1887014-12-1 |
NCIT ID | C129687 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Azacitidine + Olutasidenib | Azacitidine Olutasidenib | 0 | 3 |
Cisplatin + Gemcitabine + Olutasidenib | Cisplatin Gemcitabine Olutasidenib | 0 | 1 |
Cytarabine + Olutasidenib | Cytarabine Olutasidenib | 0 | 1 |
Decitabine + Olutasidenib | Decitabine Olutasidenib | 0 | 1 |
Decitabine and Cedazuridine + Olutasidenib | Decitabine and Cedazuridine Olutasidenib | 0 | 2 |
Nivolumab + Olutasidenib | Nivolumab Olutasidenib | 0 | 1 |
Olutasidenib | Olutasidenib | 10 | 5 |
Olutasidenib + Temozolomide | Olutasidenib Temozolomide | 0 | 1 |